stockrowEnliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Return on assets
Enliven Therapeutics, Inc.'s return on assets over the twelve months to 30 June 2026 was −15.0%, up 10.9 percentage points from fiscal 2025 (−25.9%). Over the past ten years it has ranged from −294.3% (fiscal 2018) to 0.00% (fiscal 2017); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −25.9% | 3.93 |
| FY2024 | −29.8% | 10.52 |
| FY2023 | −40.3% | 2.26 |
| FY2022 | −42.6% | 13.13 |
| FY2021 | −55.7% | 23.59 |
| FY2020 | −79.3% | 35.16 |
| FY2019 | −114.5% | 179.83 |
| FY2018 | −294.3% | (294.28) |
| FY2017 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. | −15.0% |
| DNLI Denali Therapeutics Inc. compare | −27.2% |
| CELC Celcuity, Inc. compare | −44.8% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)